Skye Bioscience (SKYE)

• Market cap: $81.9M
• 1 day: -5.59%
• 5 days: -20.35%
• 1 month: -36.92%
• 3 months: -14.01%
• 6 months: -69.76%
• Year to date: -78.72%
• 1 year: -78.72%
• 5 years: -78.72%
• 10 years: -78.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 11

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

47% more call options, than puts

Call options by funds: $87K | Put options by funds: $59K

16% more funds holding

Funds holding: 62 [Q2] → 72 (+10) [Q3]

7.18% less ownership

Funds ownership: 91.98% [Q2] → 84.81% (-7.18%) [Q3]

51% less capital invested

Capital invested by funds: $207M [Q2] → $101M (-$106M) [Q3]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 641% upside
• Avg. target: $20 641% upside
• High target: $20 641% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Scotiabank George Farmer 20% 1-year accuracy 4 / 20 met price target

641% upside $20

Sector Outperform Initiated

30 Sept 2024